Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LABR-312 for restenosis prevention in diabetic PCI
NCT02645799Phase 2Unknown
- Sponsor
- BioRest
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of Liposomal alendronate in coronary artery restenosis, sponsored by BioRest. Status: unknown.
02
Drugs
Liposomal alendronate
03
Conditions
coronary artery restenosis
Beyond the preview
Go deeper on NCT02645799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02645799.